Humacyte, Inc. reported total revenues of $301,000 for the quarter and $818,000 for the first six months of 2025 from sales and collaborative research agreements. They have gained approval for their product Symvess in 82 civilian hospitals and 35 Military Treatment Facilities and 160 U.S. Department of Veterans Affairs hospitals. A conference call will be held today at 8:00 am ET.

During the second quarter of 2025, Humacyte has seen significant growth in VAC approvals for Symvess, with 82 civilian hospitals now eligible to purchase the product. They have also received ECAT approval, expanding access to 35 Military Treatment Facilities and 160 VA hospitals. The company experienced an increase in July product sales, exceeding sales from the first half of the year.

Humacyte’s V007 trial data was highlighted at a major vascular surgery conference, showing superior functional patency of the ATEV over the autologous fistula control group in high-risk patients. The company has enrolled 100 patients in the V012 Phase 3 trial for dialysis and plans to submit a supplemental BLA to expand Symvess’ label for AV access in hemodialysis.

Financially, Humacyte reported $0.3 million in revenue for the quarter, with $0.1 million from Symvess sales. They implemented cost reductions to extend cash runway and align with key business objectives. Net loss was $37.7 million for the quarter, but the company retains cash, cash equivalents, and restricted cash of $88.4 million as of June 30, 2025.

Read more at GlobeNewswire: Humacyte Announces Second Quarter 2025 Financial Results